361 related articles for article (PubMed ID: 27541026)
1. Dynamic 2-Deoxy-2-[
Kristian A; Holtedahl JE; Torheim T; Futsaether C; Hernes E; Engebraaten O; Mælandsmo GM; Malinen E
Mol Imaging Biol; 2017 Apr; 19(2):271-279. PubMed ID: 27541026
[TBL] [Abstract][Full Text] [Related]
2. Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts.
Kristian A; Revheim ME; Qu H; Mælandsmo GM; Engebråten O; Seierstad T; Malinen E
Acta Oncol; 2013 Oct; 52(7):1566-72. PubMed ID: 23984812
[TBL] [Abstract][Full Text] [Related]
3. Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis.
Røe K; Aleksandersen TB; Kristian A; Nilsen LB; Seierstad T; Qu H; Ree AH; Olsen DR; Malinen E
Acta Oncol; 2010 Oct; 49(7):914-21. PubMed ID: 20831478
[TBL] [Abstract][Full Text] [Related]
4. PET Imaging on Dynamic Metabolic Changes after Combination Therapy of Paclitaxel and the Traditional Chinese Medicine in Breast Cancer-Bearing Mice.
Chen Y; Wang L; Liu H; Song F; Xu C; Zhang K; Chen Q; Wu S; Zhu Y; Dong Y; Zhou M; Zhang H; Tian M
Mol Imaging Biol; 2018 Apr; 20(2):309-317. PubMed ID: 28795272
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice.
McLarty K; Moran MD; Scollard DA; Chan C; Sabha N; Mukherjee J; Guha A; McLaurin J; Nitz M; Houle S; Wilson AA; Reilly RM; Vasdev N
Nucl Med Biol; 2011 Oct; 38(7):953-9. PubMed ID: 21982567
[TBL] [Abstract][Full Text] [Related]
6. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.
Wahl RL; Zasadny K; Helvie M; Hutchins GD; Weber B; Cody R
J Clin Oncol; 1993 Nov; 11(11):2101-11. PubMed ID: 8229124
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography and pharmacokinetics of 2-[18F]-fluoroethyl choline for metabolic studies in breast cancer xenografts.
Kristian A; Riss P; Qu H; Milde M; Schoultz BW; Engebraaten O; Mælandsmo GM; Malinen E
Acta Oncol; 2014 Aug; 53(8):1086-92. PubMed ID: 25017377
[TBL] [Abstract][Full Text] [Related]
8. Quantitative dynamic ¹⁸FDG-PET and tracer kinetic analysis of soft tissue sarcomas.
Rusten E; Rødal J; Revheim ME; Skretting A; Bruland OS; Malinen E
Acta Oncol; 2013 Aug; 52(6):1160-7. PubMed ID: 23198721
[TBL] [Abstract][Full Text] [Related]
9. Influx rate of
Pitman KE; Alluri SR; Kristian A; Aarnes EK; Lyng H; Riss PJ; Malinen E
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2190-2198. PubMed ID: 31264167
[TBL] [Abstract][Full Text] [Related]
10. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
Shah C; Miller TW; Wyatt SK; McKinley ET; Olivares MG; Sanchez V; Nolting DD; Buck JR; Zhao P; Ansari MS; Baldwin RM; Gore JC; Schiff R; Arteaga CL; Manning HC
Clin Cancer Res; 2009 Jul; 15(14):4712-21. PubMed ID: 19584166
[TBL] [Abstract][Full Text] [Related]
11. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer.
Wuest M; Trayner BJ; Grant TN; Jans HS; Mercer JR; Murray D; West FG; McEwan AJ; Wuest F; Cheeseman CI
Nucl Med Biol; 2011 May; 38(4):461-75. PubMed ID: 21531283
[TBL] [Abstract][Full Text] [Related]
12. Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration.
Semple SI; Staff RT; Heys SD; Redpath TW; Welch AE; Ahearn TS; Hutcheon A; Gilbert FJ
Ann Oncol; 2006 Sep; 17(9):1393-8. PubMed ID: 16788001
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET/CT-based early treatment response evaluation of nanoparticle-assisted photothermal cancer therapy.
Norregaard K; Jørgensen JT; Simón M; Melander F; Kristensen LK; Bendix PM; Andresen TL; Oddershede LB; Kjaer A
PLoS One; 2017; 12(5):e0177997. PubMed ID: 28542311
[TBL] [Abstract][Full Text] [Related]
14. Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice.
Jensen MM; Erichsen KD; Björkling F; Madsen J; Jensen PB; Højgaard L; Sehested M; Kjær A
PLoS One; 2010 Sep; 5(9):e12965. PubMed ID: 20885974
[TBL] [Abstract][Full Text] [Related]
15. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
16. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
Maynard J; Ricketts SA; Gendrin C; Dudley P; Davies BR
Mol Imaging Biol; 2013 Aug; 15(4):476-85. PubMed ID: 23344784
[TBL] [Abstract][Full Text] [Related]
17. Metabolic Tumor Burden Assessed by Dual Time Point [
Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A
Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471
[TBL] [Abstract][Full Text] [Related]
18. Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.
Vergez S; Delord JP; Thomas F; Rochaix P; Caselles O; Filleron T; Brillouet S; Canal P; Courbon F; Allal BC
Clin Cancer Res; 2010 Sep; 16(17):4434-45. PubMed ID: 20660574
[TBL] [Abstract][Full Text] [Related]
19. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]